10-Q 1 me-20230930.htm 10-Q 10-Q
--03-310001804591Q22024falsethree year0001804591us-gaap:CommonClassAMember2022-04-012022-09-300001804591me:PgsMember2023-04-012023-09-300001804591us-gaap:AccountsReceivableMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591srt:MaximumMemberme:AAndRPlanMemberme:LemonaidHealthIncMember2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-06-300001804591me:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:CommonClassAMember2023-10-310001804591me:GSKMember2022-04-012022-09-300001804591srt:MinimumMember2023-04-012023-09-300001804591us-gaap:FairValueMeasurementsNonrecurringMember2022-07-012022-09-300001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2022-04-012022-09-300001804591me:PartnershipsMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591me:DevelopedTechnologyMember2023-03-310001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2022-04-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591me:EmployeeStockPurchasePlanMember2023-04-012023-09-300001804591me:AipMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001804591country:US2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591us-gaap:CommonClassBMember2023-10-310001804591us-gaap:HealthCareOtherMember2023-04-012023-09-300001804591me:OtherRegionsMember2022-04-012022-09-300001804591us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001804591us-gaap:LeaseholdImprovementsMember2023-03-310001804591us-gaap:CommonClassAMember2023-04-012023-09-300001804591me:DeferredRevenueMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-03-310001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001804591us-gaap:CommonClassBMember2023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591me:PgsMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:CommonStockMember2023-04-012023-06-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-3000018045912021-04-012022-03-310001804591srt:MaximumMember2023-09-300001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2022-04-012022-09-300001804591us-gaap:CorporateMember2022-07-012022-09-300001804591us-gaap:ServiceMember2022-07-012022-09-300001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300001804591me:IncentiveEquityPlanMemberus-gaap:CommonClassAMember2021-06-100001804591us-gaap:AdditionalPaidInCapitalMember2023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:CommonClassBMember2022-07-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2023-04-012023-09-300001804591me:IncentiveEquityPlanMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2023-09-300001804591me:ConsumerAndResearchServicesMember2022-04-012022-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591me:TwoThousandAndTwentyOneEquityIncentivePlanMember2023-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:MicroarraysMember2023-04-012023-09-300001804591me:GSKMember2023-04-012023-09-300001804591me:InternalUseSoftwareMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591me:ConsumerAndResearchServicesMember2023-07-012023-09-300001804591us-gaap:CommonClassBMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2022-03-310001804591me:AipMember2023-09-300001804591me:InternalUseSoftwareMember2022-04-012022-09-300001804591me:PIPEInvestorsMember2021-04-012022-03-310001804591me:ComputerAndSoftwareMember2023-03-310001804591me:CustomerFMember2022-04-012023-03-310001804591us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001804591us-gaap:RetainedEarningsMember2023-03-310001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2023-07-012023-09-3000018045912023-06-300001804591me:ConsumerServicesMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2022-09-300001804591country:US2023-04-012023-09-300001804591me:GSKMember2022-04-012023-03-310001804591me:EmployeeStockPurchasePlanMember2021-06-102021-06-100001804591me:CapitalizedAssetRetirementObligationsMember2023-03-310001804591us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:OtherRegionsMember2023-07-012023-09-300001804591us-gaap:CorporateMember2023-07-012023-09-300001804591us-gaap:FairValueMeasurementsNonrecurringMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:TherapeuticsMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:CustomersRelationshipsMember2023-03-310001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:ComputerAndSoftwareMember2023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMember2023-03-310001804591me:ConsumerServicesMember2022-04-012022-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:IncentiveEquityPlanMemberus-gaap:EmployeeStockOptionMember2023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2022-07-012022-09-3000018045912022-06-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001804591us-gaap:OtherRestructuringMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2022-07-012022-09-300001804591me:ConsumerAndResearchServicesMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2022-04-012022-09-300001804591me:ResearchServicesMember2022-07-012022-09-300001804591me:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-04-012023-09-300001804591us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:VGAcquisitionSponsorLLCMember2023-04-012023-09-300001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMember2023-07-012023-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591me:GSKMember2023-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2022-07-012022-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001804591us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:AipMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:EmployeeStockOptionMember2023-07-012023-09-3000018045912023-04-012023-09-300001804591me:ConsumerServicesMember2023-09-300001804591us-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:CommonClassBMember2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMember2022-07-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591srt:MaximumMember2023-07-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMemberme:CustomerBMember2022-07-012022-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591me:ResearchServicesMember2023-04-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2022-04-012023-03-310001804591us-gaap:NoncompeteAgreementsMember2023-09-300001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:ConsumerServicesMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:CommonClassAMember2023-09-300001804591me:IncentiveEquityPlanMembersrt:MinimumMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:AAndRPlanMemberus-gaap:CommonClassAMemberme:LemonaidHealthIncMember2023-09-300001804591me:VGAcquisitionSponsorLLCMember2022-04-012023-03-310001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591me:LaboratoryEquipmentAndSoftwareMember2023-09-300001804591me:AipMember2022-07-012022-09-300001804591us-gaap:RetainedEarningsMember2022-04-012022-06-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2023-04-012023-09-300001804591country:GB2022-07-012022-09-300001804591me:ConsumerAndResearchServicesMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2022-04-012022-09-300001804591me:ConsumerServicesMember2022-07-012022-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2022-04-012022-09-300001804591me:AipMember2023-03-310001804591srt:MaximumMemberme:AAndRPlanMemberus-gaap:CommonClassAMemberme:NonEmployeeDirectorsMemberme:LemonaidHealthIncMember2023-09-300001804591us-gaap:RetainedEarningsMember2022-07-012022-09-300001804591me:RelinquishmentTriggeringEventMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2023-11-012023-11-010001804591me:GSKMember2023-03-310001804591us-gaap:SubsequentEventMemberme:AmendmentToGskAgreementMember2023-10-270001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2022-04-012022-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2023-04-012023-09-300001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMember2023-03-310001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2023-07-012023-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591srt:MaximumMemberme:AAndRPlanMemberus-gaap:CommonClassAMember2023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:CorporateMember2022-04-012022-09-300001804591us-gaap:CommonStockMember2022-07-012022-09-300001804591me:CowenAndCompanyLlcMembersrt:MaximumMemberme:SalesAgreementMember2023-02-060001804591country:CA2022-07-012022-09-3000018045912022-04-012022-06-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:PatentsMember2023-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591me:InternalUseSoftwareMember2022-07-012022-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2023-07-012023-09-3000018045912022-03-310001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMember2023-09-300001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2023-07-012023-09-300001804591srt:MinimumMember2022-07-012022-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:ServiceMember2023-04-012023-09-300001804591us-gaap:PatentsMember2023-03-310001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2023-04-012023-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591country:CA2022-04-012022-09-300001804591me:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-09-300001804591me:AipMember2022-04-012022-09-300001804591us-gaap:CommonStockMember2023-06-3000018045912023-02-062023-02-060001804591us-gaap:RetainedEarningsMember2023-06-300001804591me:VariableInterestEntitiesMember2022-07-012022-09-300001804591me:TherapeuticsMember2022-04-012022-09-300001804591me:TrademarkMember2023-03-310001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2023-07-012023-09-300001804591country:GB2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMemberme:CustomerBMember2023-04-012023-09-300001804591me:LemonaidHealthLimitedMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:EmployeeStockOptionMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:CorporateMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591us-gaap:ServiceMember2022-04-012022-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2023-03-310001804591us-gaap:CommonStockMember2023-07-012023-09-300001804591me:CustomerFMember2023-04-012023-09-300001804591country:CA2023-04-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001804591me:PartnershipsMember2023-09-300001804591me:DevelopedTechnologyMember2023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-03-310001804591srt:MaximumMember2023-04-012023-09-300001804591country:US2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-09-300001804591me:VariableInterestEntitiesMember2023-04-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-09-300001804591us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:NoncompeteAgreementsMember2023-03-310001804591country:CA2023-07-012023-09-300001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2022-04-012022-09-300001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001804591us-gaap:EmployeeStockOptionMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-09-300001804591me:OtherRegionsMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2022-06-300001804591srt:MinimumMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-06-3000018045912022-04-012023-03-310001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2023-07-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2023-07-012023-09-300001804591us-gaap:CommonStockMember2023-03-310001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-09-3000018045912023-03-310001804591me:FurnitureAndOfficeEquipmentMember2023-03-310001804591me:CustomersRelationshipsMember2023-09-300001804591me:ResearchServicesMember2023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2022-04-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:AccountsPayableMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMember2023-09-300001804591us-gaap:CommonClassBMember2022-04-012022-09-300001804591country:GB2023-07-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMemberme:CustomerBMember2022-04-012022-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:VariableInterestEntitiesMember2022-04-012022-09-300001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001804591us-gaap:CommonStockMember2023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2023-04-012023-09-300001804591us-gaap:LeaseholdImprovementsMember2023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591me:GSKMember2022-10-312022-10-310001804591me:CustomerCMember2022-04-012023-03-310001804591us-gaap:FairValueMeasurementsNonrecurringMember2023-07-012023-09-300001804591me:ResearchServicesMember2023-07-012023-09-300001804591country:GB2023-04-012023-09-300001804591me:ResearchServicesMember2023-03-310001804591me:LaboratoryEquipmentAndSoftwareMember2023-03-310001804591us-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:RetainedEarningsMember2023-04-012023-06-300001804591srt:MinimumMember2022-04-012022-09-300001804591us-gaap:HealthCareOtherMember2022-04-012022-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591country:US2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2022-04-012022-09-300001804591me:GSKMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2022-04-012022-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:InternalUseSoftwareMember2023-07-012023-09-300001804591me:OtherRegionsMember2022-07-012022-09-300001804591me:TrademarkMember2023-09-300001804591us-gaap:CommonClassAMember2022-07-012022-09-300001804591me:ConsumerServicesMember2023-03-3100018045912022-04-012022-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-3000018045912022-09-300001804591me:GSKMember2022-07-012022-09-300001804591me:CustomerCMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2022-07-012022-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591me:TwoThousandAndSixEquityIncentivePlanMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2023-07-012023-09-300001804591srt:MinimumMemberme:AAndRPlanMemberme:LemonaidHealthIncMember2023-04-012023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:FormerLemonaidOfficerMember2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-04-012022-06-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2022-04-012022-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591srt:MinimumMemberme:AAndRPlanMemberus-gaap:CommonClassAMember2023-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2021-06-100001804591me:IncentiveEquityPlanMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001804591us-gaap:AccountsPayableMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591us-gaap:CommonClassAMember2023-03-310001804591us-gaap:AdditionalPaidInCapitalMember2023-03-310001804591srt:MaximumMember2022-07-012022-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:DeferredRevenueMember2023-04-012023-09-300001804591me:AipMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591me:LemonaidHealthIncMember2021-11-012021-11-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:VariableInterestEntitiesMember2023-07-012023-09-300001804591me:VGAcquisitionSponsorLLCMembersrt:MinimumMemberus-gaap:CommonClassAMember2023-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2022-04-012022-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:CommonClassBMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-06-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:AccountsReceivableMember2022-04-012022-09-300001804591us-gaap:FairValueMeasurementsNonrecurringMember2023-04-012023-09-300001804591srt:MinimumMember2023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2023-04-012023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:VGAcquisitionSponsorLLCMembersrt:MaximumMember2023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001804591me:TwoThousandAndTwentyOneEquityIncentivePlanMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591me:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-04-012022-09-300001804591me:CapitalizedAssetRetirementObligationsMember2023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591srt:MinimumMemberme:AAndRPlanMemberus-gaap:CommonClassAMemberme:NonEmployeeDirectorsMemberme:LemonaidHealthIncMember2023-09-300001804591me:EmployeeStockPurchasePlanMember2021-06-100001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2022-07-012022-09-3000018045912023-04-012023-06-300001804591me:PgsMember2022-04-012022-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2022-07-012022-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2023-07-012023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591me:FurnitureAndOfficeEquipmentMember2023-09-300001804591me:ResearchServicesMember2022-04-012022-09-3000018045912023-07-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2022-07-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:ServiceMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:TherapeuticsMember2023-04-012023-09-3000018045912022-07-012022-09-300001804591me:LemonaidHealthLimitedMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2022-04-012022-09-300001804591srt:MaximumMember2022-04-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:PgsMember2022-07-012022-09-3000018045912023-09-300001804591us-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:TherapeuticsMember2022-07-012022-09-300001804591us-gaap:OtherRestructuringMember2023-07-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-30xbrli:purexbrli:sharesme:Voteiso4217:USDxbrli:sharesiso4217:USD

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO___________

Commission File Number 001-39587

 

23ANDME HOLDING CO.

(Exact name of Registrant as specified in its Charter)

 

Delaware

87-1240344

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

349 Oyster Point Boulevard
South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

(650) 938-6300

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, $0.0001 par value per share

ME

The Nasdaq Global Select Market

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

As of October 31, 2023, there were 311,613,095 shares of Class A common stock, $0.0001 par value per share, and 167,491,460 shares of Class B common stock, $0.0001 par value per share, issued and outstanding.

 

 

 

 


Table of Contents

 

23ANDME HOLDING CO.

TABLE OF CONTENTS

 

 

PAGE

PART I. FINANCIAL INFORMATION

 

Item 1.

Financial Statements

4

 

Condensed Consolidated Balance Sheets

4

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

5

 

Condensed Consolidated Statements of Stockholders’ Equity

6

 

Condensed Consolidated Statements of Cash Flows

7

 

Notes to the Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

48

Item 4.

Controls and Procedures

48

 

PART II

 

Item 1.

Legal Proceedings

49

Item 1A.

Risk Factors

49

Item 2.

Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

49

Item 3.

Defaults Upon Senior Securities

49

Item 4.

Mine Safety Disclosures

49

Item 5.

Other Information

49

Item 6.

Exhibits

50

 

 

SIGNATURES

51

 

 


Table of Contents

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Form 10-Q”), including, without limitation, statements under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Generally, statements that are not historical facts, including statements concerning 23andMe Holding Co.’s (the “Company,” “23andMe,” “we,” “us,” or “our”) possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. In some instances, these forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, words like “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations.

The forward-looking statements contained in this Form 10-Q are based on our current expectations and beliefs, which we believe to be reasonable, concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, without limitation, those factors described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on May 25, 2023, and our subsequent reports filed with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition, and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods.

3


Table of Contents

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

23ANDME HOLDING CO.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

 

 

September 30,

 

 

March 31,

 

 

 

2023

 

 

2023

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

256,386

 

 

$

386,849

 

Restricted cash

 

 

1,399

 

 

 

1,399

 

Accounts receivable, net

 

 

1,501

 

 

 

1,897

 

Inventories

 

 

14,979

 

 

 

10,247

 

Deferred cost of revenue

 

 

5,782

 

 

 

5,376

 

Prepaid expenses and other current assets

 

 

17,948

 

 

 

19,224

 

Total current assets

 

 

297,995

 

 

 

424,992

 

Property and equipment, net

 

 

32,805

 

 

 

38,608

 

Operating lease right-of-use assets

 

 

52,549

 

 

 

56,078

 

Restricted cash, noncurrent

 

 

6,974

 

 

 

6,974

 

Internal-use software, net

 

 

18,971

 

 

 

15,661

 

Intangible assets, net

 

 

37,835

 

 

 

45,520

 

Goodwill

 

 

351,744

 

 

 

351,744

 

Other assets

 

 

2,357

 

 

 

3,021

 

Total assets

 

$

801,230

 

 

$

942,598

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable (includes related party amounts of nil and $3,186, respectively)

 

$

8,546

 

 

$

12,924

 

Accrued expenses and other current liabilities (includes related party amounts of $13,732 and $8,738, respectively)

 

 

44,686

 

 

 

66,430

 

Deferred revenue (includes related party amounts of nil and $11,753, respectively)

 

 

40,283

 

 

 

62,521

 

Operating lease liabilities

 

 

8,086

 

 

 

7,541

 

Total current liabilities

 

 

101,601

 

 

 

149,416

 

Operating lease liabilities, noncurrent

 

 

72,963

 

 

 

77,763

 

Other liabilities

 

 

1,415

 

 

 

1,480

 

Total liabilities

 

 

175,979

 

 

 

228,659

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

Preferred stock - par value $0.0001, 10,000,000 shares authorized as of September 30, 2023 and March 31, 2023; zero shares issued and outstanding as of September 30, 2023 and March 31, 2023

 

 

 

 

 

 

Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 311,339,539 and 293,020,474 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively; Class B shares, 350,000,000 shares authorized, 167,491,460 and 168,179,488 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively

 

 

48

 

 

 

46

 

Additional paid-in capital

 

 

2,311,481

 

 

 

2,220,897

 

Accumulated other comprehensive loss

 

 

 

 

 

(620

)

Accumulated deficit

 

 

(1,686,278

)

 

 

(1,506,384

)

Total stockholders’ equity

 

 

625,251

 

 

 

713,939

 

Total liabilities and stockholders’ equity

 

$

801,230

 

 

$

942,598

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4


Table of Contents

 

23ANDME HOLDING CO.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Six Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue (includes related party revenue of $1,082 and $14,925 for the three months ended September 30, 2023 and 2022, respectively, and $11,753 and $23,190 for the six months ended September 30, 2023 and 2022, respectively)

 

$

49,999

 

 

$

75,659

 

 

$

110,863

 

 

$

140,172

 

Cost of revenue (includes related party cost of $20 and $(271) for the three months ended September 30, 2023 and 2022, respectively, and $295 and $(510) for the six months ended September 30, 2023 and 2022, respectively)

 

 

28,270

 

 

 

37,386

 

 

 

58,453

 

 

 

76,409

 

Gross profit

 

 

21,729

 

 

 

38,273

 

 

 

52,410

 

 

 

63,763

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development (includes related party expenses of $4,907 and $2,717 for the three months ended September 30, 2023 and 2022, respectively, and $8,208 and $6,266 for the six months ended September 30, 2023 and 2022, respectively)

 

 

54,588

 

 

 

52,598

 

 

 

116,917

 

 

 

104,607

 

Sales and marketing

 

 

18,328

 

 

 

24,835

 

 

 

40,986

 

 

 

58,269

 

General and administrative

 

 

25,290

 

 

 

28,881

 

 

 

76,030

 

 

 

58,524

 

Restructuring and other charges

 

 

2,654

 

 

 

 

 

 

6,871

 

 

 

 

Total operating expenses

 

 

100,860

 

 

 

106,314

 

 

 

240,804

 

 

 

221,400

 

Loss from operations

 

 

(79,131

)

 

 

(68,041

)

 

 

(188,394

)

 

 

(157,637

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

3,752

 

 

 

1,392

 

 

 

8,059

 

 

 

1,637

 

Other income (expense), net

 

 

145

 

 

 

(687

)

 

 

477

 

 

 

(1,122

)

Loss before income taxes

 

 

(75,234

)

 

 

(67,336

)

 

 

(179,858

)

 

 

(157,122

)

Provision for (benefit from) income taxes

 

 

36

 

 

 

(1,271

)

 

 

36

 

 

 

(1,525

)

 Net loss

 

 

(75,270

)

 

 

(66,065

)

 

 

(179,894

)

 

 

(155,597

)

Other comprehensive income, net of tax

 

 

954

 

 

 

829

 

 

 

620

 

 

 

1,453

 

Total comprehensive loss

 

$

(74,316

)

 

$

(65,236

)

 

$

(179,274

)

 

$

(154,144

)

Net loss per share of Class A and Class B common stock attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.16

)

 

$

(0.15

)

 

$

(0.38

)

 

$

(0.35

)

Weighted-average shares used to compute net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

474,858,266

 

 

 

449,899,537

 

 

 

468,592,009

 

 

 

448,211,708

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


Table of Contents

 

23ANDME HOLDING CO.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share and per share data)

(Unaudited)

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated Other Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’ Equity

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

(Deficit)

 

Balance as of March 31, 2023

 

 

461,199,962

 

 

$

46

 

 

$

2,220,897

 

 

$

(620

)

 

$

(1,506,384

)

 

$

713,939

 

Issuance of common stock upon exercise of stock options

 

 

180,718

 

 

 

 

 

 

85

 

 

 

 

 

 

 

 

 

85

 

Issuance of common stock upon release of restricted stock units

 

 

1,812,802

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan

 

 

8,961,053

 

 

 

1

 

 

 

18,629

 

 

 

 

 

 

 

 

 

18,630

 

Net share settlements for stock-based minimum tax withholdings

 

 

(58,985

)

 

 

 

 

 

(121

)

 

 

 

 

 

 

 

 

(121

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

47,915

 

 

 

 

 

 

 

 

 

47,915

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(334

)

 

 

 

 

 

(334

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(104,624

)

 

 

(104,624

)

Balance as of June 30, 2023

 

 

472,095,550

 

 

$

47

 

 

$

2,287,405

 

 

$

(954

)

 

$

(1,611,008

)

 

$

675,490

 

Issuance of common stock upon exercise of stock options

 

 

828,561

 

 

 

 

 

 

388

 

 

 

 

 

 

 

 

 

388

 

Issuance of common stock upon release of restricted stock units

 

 

4,358,378

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan

 

 

57,996

 

 

 

 

 

 

102

 

 

 

 

 

 

 

 

 

102

 

Net share settlements for stock-based minimum tax withholdings

 

 

(19,022

)

 

 

 

 

 

(22

)

 

 

 

 

 

 

 

 

(22

)

Issuance of common stock under employee stock purchase plan

 

 

1,509,536

 

 

 

 

 

 

1,411

 

 

 

 

 

 

 

 

 

1,411

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

22,198

 

 

 

 

 

 

 

 

 

22,198

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

954

 

 

 

 

 

 

954

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(75,270

)

 

 

(75,270

)

Balance as of September 30, 2023

 

 

478,830,999

 

 

$

48

 

 

$

2,311,481

 

 

$

 

 

$

(1,686,278

)

 

$

625,251

 

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated Other Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’ Equity

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

(Deficit)

 

Balance as of March 31, 2022

 

 

448,812,321

 

 

$

45

 

 

$

2,110,160

 

 

$

179

 

 

$

(1,194,728

)

 

$

915,656

 

Issuance of common stock upon exercise of stock options

 

 

1,065,784

 

 

 

 

 

 

1,533

 

 

 

 

 

 

 

 

 

1,533

 

Issuance of common stock upon release of restricted stock units

 

 

1,461,448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net share settlements for stock-based minimum tax withholdings

 

 

(14,036

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

25,915

 

 

 

 

 

 

 

 

 

25,915

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

624

 

 

 

 

 

 

624

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(89,532

)

 

 

(89,532

)

Balance as of June 30, 2022

 

 

451,325,517

 

 

$

45

 

 

$

2,137,608

 

 

$

803

 

 

$

(1,284,260

)

 

$

854,196

 

Issuance of common stock upon exercise of stock options

 

 

1,430,629

 

 

 

 

 

 

2,498

 

 

 

 

 

 

 

 

 

2,498

 

Issuance of common stock upon release of restricted stock units

 

 

1,580,591

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net share settlements for stock-based minimum tax withholdings

 

 

(14,038

)

 

 

 

 

 

(86

)

 

 

 

 

 

 

 

 

(86

)

Issuance of common stock under employee stock purchase plan

 

 

1,130,337

 

 

 

 

 

 

3,238

 

 

 

 

 

 

 

 

 

3,238

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

24,710

 

 

 

 

 

 

 

 

 

24,710

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

829

 

 

 

 

 

 

829

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(66,065

)

 

 

(66,065

)

Balance as of September 30, 2022

 

 

455,453,036

 

 

$

45

 

 

$